Funding an academic exit, leaving ecology and evolutionary biology for biomedical engineering, and moving from business development to entrepreneurship shaped 3 careers. hubs.li/Q04B_RsX0

Pfizer is saying goodbye to an unspecified number of employees across its manufacturing operations, a spokesperson confirmed to BioSpace via email on Tuesday. hubs.li/Q04BV6FC0

Looking for a remote biopharma position? Check out the BioSpace list of eight companies hiring life sciences professionals like you. hubs.li/Q04BTFj50

Just one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the problem. hubs.li/Q04BTDZd0

Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug approvals this year. hubs.li/Q04BTCRy0

Post hoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients. hubs.li/Q04BTgQm0

A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy. hubs.li/Q04BTgf20

China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field. hubs.li/Q04BTf6H0

Compensation can feel like a verdict on your value. Executive coach Angela Justice explains why companies are usually pricing the job, not the person doing it—and how understanding the difference can help you make better career decisions. hubs.li/Q04BT7ST0

Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania. hubs.li/Q04BLx5Y0

Enlivex is cutting about 60% of staff to reduce costs and focus on mid-stage development of its knee osteoarthritis cell therapy, Allocetra. After another disappointing duravyu readout in wet AMD, EyePoint is reprioritizing and cutting about 53% of staff. hubs.li/Q04BLnPS0

METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.

Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio. hubs.li/Q04BK06b0

The 3rd quarter offered positive signals for job seekers and talent acquisition teams. Explore BioSpace’s Biopharma Job Market Report Q3 2026 to get a closer look at hiring trends, workforce reductions and the evolving employment landscape. Download here: hubs.li/Q04BJZRh0

Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession. hubs.li/Q04BJWmX0

In this bonus episode, BioSpace Vice President of Marketing Chantal Dresner and Angela Gabriel, content manager, life sciences careers, discuss how the job market shaped up in Q3 and what Q4 might hold. hubs.li/Q04BKTLd0

The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API production at the Frankfurt campus. hubs.li/Q04BJNRF0

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to its potential in diabetic macular edema. hubs.li/Q04BJNfg0

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market. hubs.li/Q04Bz2-_0

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone. hubs.li/Q04ByYw50